Siren, L.L.C.
13F Reported Value
ⓘ$4.9B
incl. option notional
Equity Holdings
ⓘ$4.9B
Option Notional
ⓘ$15.6M
$0 puts / $15.6M calls
Holdings
117
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Siren, L.L.C. disclosed 117 positions worth $4.9B in its Form 13F-HR for Q2 2026 — $4.9B in common stock plus $15.6M of put/call option positions (reported at underlying notional value, not premium at risk), led by $SRRK (Scholar Rock Holding Corp) at 10.7% of the equity portfolio, followed by $KYMR and $ERAS. During the quarter the fund opened 26 new positions and exited 9 — including a new stake in $PBLS and a full exit from $CNTA. The portfolio is most concentrated in Healthcare (93.2% of disclosed assets). All figures are sourced directly from Siren, L.L.C.’s Form 13F-HR filing with the SEC under CIK 2005245.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$526.6M9,575,013 sh - 28.4#2,557
Quality
$336.7M2,935,830 sh - —
Quality
$208.8M11,397,781 sh - —
Quality
$203.5M1,655,374 sh - 17.6
Quality
$193.2M6,179,364 sh - —
Quality
$168.6M900,000 sh - —
Quality
$166.4M5,602,970 sh - 38.7
Quality
$139.8M1,715,476 sh - —
Quality
$132.5M465,000 sh - —
Quality
$129.4M3,184,629 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Scholar Rock Holding Corp$SRRK | — | $526.6M | 9,575,013 |
 Kymera Therapeutics, Inc.$KYMR | 28.4#2,557 | $336.7M | 2,935,830 |
 Erasca, Inc.$ERAS | — | $208.8M | 11,397,781 |
 Veradermics, Inc$MANE | — | $203.5M | 1,655,374 |
 Tango Therapeutics, Inc.$TNGX | 17.6 | $193.2M | 6,179,364 |
 Revolution Medicines, Inc.$RVMD | — | $168.6M | 900,000 |
 Bicara Therapeutics Inc.$BCAX | — | $166.4M | 5,602,970 |
 ARROWHEAD PHARMACEUTICALS, INC.$ARWR | 38.7 | $139.8M | 1,715,476 |
 BeOne Medicines Ltd.$ONC | — | $132.5M | 465,000 |
 Edgewise Therapeutics, Inc.$EWTX | — | $129.4M | 3,184,629 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Siren, L.L.C.'s 117 positions.
Showing top 10 of 117 holdings.
Sector Allocation
Healthcare
$4.6B
Technology
$226.1M
Industrials
$56.5M
Financials
$42.8M
Consumer Discretionary
$7.7M
Communication Services
$2.8M
Real Estate
$1.5M
Full Holdings — Siren, L.L.C. (Q2 2026)
All 117 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $SRRK | Scholar Rock Holding Corp | $526.6M | 10.7% | -12% | — |
| 2 | $KYMR | Kymera Therapeutics, Inc. | $336.7M | 6.8% | -8% | 28.4 |
| 3 | $ERAS | Erasca, Inc. | $208.8M | 4.2% | +1% | — |
| 4 | $MANE | Veradermics, Inc | $203.5M | 4.1% | +10% | — |
| 5 | $TNGX | Tango Therapeutics, Inc. | $193.2M | 3.9% | +9% | 17.6 |
| 6 | $RVMD | Revolution Medicines, Inc. | $168.6M | 3.4% | -19% | — |
| 7 | $BCAX | Bicara Therapeutics Inc. | $166.4M | 3.4% | -3% | — |
| 8 | $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $139.8M | 2.8% | +6% | 38.7 |
| 9 | $ONC | BeOne Medicines Ltd. | $132.5M | 2.7% | +0% | — |
| 10 | $EWTX | Edgewise Therapeutics, Inc. | $129.4M | 2.6% | -28% | — |
| 11 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $126.2M | 2.6% | +57% | 33.9 |
| 12 |  $LXRX | LEXICON PHARMACEUTICALS, INC. | $106.3M | 2.2% | +0% | 33.7 |
| 13 |  $ELVN | Enliven Therapeutics, Inc. | $90.1M | 1.8% | +138% | — |
| 14 |  $SYRE | Spyre Therapeutics, Inc. | $86.0M | 1.8% | +18% | — |
| 15 |  $PBLS | Parabilis Medicines, Inc. | $81.9M | 1.7% | NEW | — |
| 16 |  $XENE | Xenon Pharmaceuticals Inc. | $79.6M | 1.6% | +0% | 24 |
| 17 |  $SLDB | Solid Biosciences Inc. | $76.8M | 1.6% | +0% | — |
| 18 |  $ABVX | Abivax S.A. | $76.8M | 1.6% | NEW | — |
| 19 |  $COAG | Hemab Therapeutics Holdings, Inc. | $76.6M | 1.6% | NEW | — |
| 20 |  $RCUS | Arcus Biosciences, Inc. | $74.6M | 1.5% | -20% | 8.5 |
| 21 |  $COGT | Cogent Biosciences, Inc. | $72.0M | 1.5% | +9% | — |
| 22 |  $RLAY | Relay Therapeutics, Inc. | $68.3M | 1.4% | NEW | 19.5 |
| 23 |  $TSHA | Taysha Gene Therapies, Inc. | $67.1M | 1.4% | +12% | 4.9 |
| 24 |  $DFTX | Definium Therapeutics, Inc. | $66.8M | 1.4% | +54% | — |
| 25 |  $STOK | Stoke Therapeutics, Inc. | $65.3M | 1.3% | +0% | 24.9 |
| 26 |  $IRON | Disc Medicine, Inc. | $65.0M | 1.3% | -10% | — |
| 27 |  $CYTK | CYTOKINETICS INC | $64.7M | 1.3% | +24% | 28.1 |
| 28 |  $SEPN | Septerna, Inc. | $63.6M | 1.3% | -5% | 59.2 |
| 29 |  $OLMA | Olema Pharmaceuticals, Inc. | $60.8M | 1.2% | +2% | — |
| 30 |  $CRNX | Crinetics Pharmaceuticals, Inc. | $53.2M | 1.1% | -25% | 25.5 |
| 31 |  $KLRA | Kailera Therapeutics, Inc. | $48.8M | 1.0% | NEW | — |
| 32 |  $DYN | Dyne Therapeutics, Inc. | $47.3M | 1.0% | -4% | — |
| 33 |  $GPCR | Structure Therapeutics Inc. | $46.9M | 0.9% | -34% | — |
| 34 |  $TBLA | Taboola.com Ltd. | $42.1M | 0.9% | -16% | — |
| 35 |  $PVLA | PALVELLA THERAPEUTICS, INC. | $39.3M | 0.8% | +0% | — |
| 36 |  $SLN | Silence Therapeutics plc | $36.4M | 0.7% | +14% | — |
| 37 |  $DNLI | Denali Therapeutics Inc. | $35.9M | 0.7% | +0% | — |
| 38 |  $RELY | Remitly Global, Inc. | $34.6M | 0.7% | +0% | 72.5 |
| 39 |  $CGEM | Cullinan Therapeutics, Inc. | $34.5M | 0.7% | +59% | — |
| 40 |  $COF | CAPITAL ONE FINANCIAL CORP | $34.4M | 0.7% | NEW | 62.4 |
| 41 |  $TRVI | Trevi Therapeutics, Inc. | $33.3M | 0.7% | +0% | — |
| 42 |  $ORIC | Oric Pharmaceuticals, Inc. | $32.5M | 0.7% | +0% | — |
| 43 |  $GOOG | Alphabet Inc. | $32.2M | 0.7% | +37% | 78.2 |
| 44 |  $DBVT | DBV Technologies S.A. | $30.5M | 0.6% | +0% | — |
| 45 |  $ABSI | Absci Corp | $28.7M | 0.6% | +37% | 7 |
| 46 |  $SION | Sionna Therapeutics, Inc. | $26.9M | 0.6% | +104% | — |
| 47 |  $RAPP | Rapport Therapeutics, Inc. | $26.7M | 0.5% | +0% | — |
| 48 |  $AMLX | Amylyx Pharmaceuticals, Inc. | $26.6M | 0.5% | +20% | 8.7 |
| 49 |  $ANNX | Annexon, Inc. | $25.5M | 0.5% | +13% | — |
| 50 |  $MNPR | Monopar Therapeutics | $25.0M | 0.5% | +0% | — |
| 51 |  $ORKA | Oruka Therapeutics, Inc. | $23.8M | 0.5% | NEW | — |
| 52 |  $SPTX | Seaport Therapeutics, Inc. | $23.8M | 0.5% | NEW | — |
| 53 |  $DMRA | Damora Therapeutics, Inc. | $23.4M | 0.5% | +0% | — |
| 54 |  $TYRA | Tyra Biosciences, Inc. | $23.2M | 0.5% | NEW | — |
| 55 |  $ZURA | Zura Bio Ltd | $22.0M | 0.5% | +0% | — |
| 56 |  $TSM | TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD | $21.3M | 0.4% | +6% | — |
| 57 |  $NVDA | NVIDIA CORP | $19.0M | 0.4% | +7% | 85.9 |
| 58 |  $RZLT | Rezolute, Inc. | $17.3M | 0.3% | +0% | — |
| 59 |  $MPLT | MapLight Therapeutics, Inc. | $16.1M | 0.3% | +0% | — |
| 60 |  $NMRA | Neumora Therapeutics, Inc. | $14.4M | 0.3% | +0% | — |
| 61 |  $NBIS | Nebius Group N.V. | $14.4M | 0.3% | -54% | — |
| 62 |  $MSFT | MICROSOFT CORP | $14.0M | 0.3% | -9% | 79.8 |
| 63 |  $CTMX | CytomX Therapeutics, Inc. | $13.0M | 0.3% | +0% | 8.7 |
| 64 |  $GENB | Generate Biomedicines, Inc. | $12.4M | 0.3% | +0% | — |
| 65 |  $IKT | Inhibikase Therapeutics, Inc. | $11.9M | 0.2% | +0% | — |
| 66 |  $ADAG | Adagene Inc. | $11.2M | 0.2% | NEW | — |
| 67 |  $ENGN | enGene Therapeutics Inc. | $10.8M | 0.2% | +19% | — |
| 68 |  $WHWK | Whitehawk Therapeutics, Inc. | $10.7M | 0.2% | +12% | 26.4 |
| 69 |  $DDOG | Datadog, Inc. | $10.4M | 0.2% | -26% | 71.4 |
| 70 |  $NOW | ServiceNow, Inc. | $9.9M | 0.2% | +15% | 72.9 |
| 71 |  $AVGO | Broadcom Inc. | $9.4M | 0.2% | +67% | 84.5 |
| 72 |  $IONQ | IonQ, Inc. | $9.1M | 0.2% | +0% | 30.2 |
| 73 | $MSFTCALL | MICROSOFT CORP | $9.0M | — | NEW | 79.8 |
| 74 |  $FROG | JFrog Ltd | $8.7M | 0.2% | -26% | — |
| 75 |  $OCS | Oculis Holding AG | $8.7M | 0.2% | NEW | — |
| 76 |  $IREN | IREN Ltd | $8.0M | 0.2% | +306% | 46.3 |
| 77 |  $AMZN | AMAZON COM INC | $7.7M | 0.2% | -30% | 68.7 |
| 78 |  $CRWD | CrowdStrike Holdings, Inc. | $7.6M | 0.1% | -57% | 67.7 |
| 79 |  $DSGN | Design Therapeutics, Inc. | $7.6M | 0.1% | NEW | — |
| 80 |  $PDD | PDD Holdings Inc. | $7.2M | 0.1% | +14% | — |
| 81 |  $MSLE | Satellos Bioscience Inc. | $6.9M | 0.1% | +0% | — |
| 82 |  $DT | Dynatrace, Inc. | $6.8M | 0.1% | +3% | 64.4 |
| 83 |  $AAPLCALL | Apple Inc. | $6.7M | — | NEW | 76.4 |
| 84 |  $TENX | TENAX THERAPEUTICS, INC. | $6.2M | 0.1% | +0% | — |
| 85 |  $VTVT | vTv Therapeutics Inc. | $6.1M | 0.1% | +0% | — |
| 86 |  $ELOX | Eloxx Pharmaceuticals, Inc. | $5.6M | 0.1% | NEW | — |
| 87 |  $AGMB | Agomab Therapeutics NV | $5.3M | 0.1% | +0% | — |
| 88 |  $BABA | Alibaba Group Holding Ltd | $4.8M | 0.1% | NEW | — |
| 89 |  $KRRO | Korro Bio, Inc. | $4.6M | 0.1% | +0% | 14.1 |
| 90 |  $CLBT | Cellebrite DI Ltd. | $4.5M | 0.1% | +0% | — |
| 91 |  $IVVD | Invivyd, Inc. | $4.4M | 0.1% | +25% | 29.7 |
| 92 |  $OUST | Ouster, Inc. | $4.2M | 0.1% | NEW | 36.2 |
| 93 |  $PALI | PALISADE BIO, INC. | $4.2M | 0.1% | NEW | — |
| 94 |  $AEVA | Aeva Technologies, Inc. | $4.2M | 0.1% | +32% | 28.8 |
| 95 |  $SEER | Seer, Inc. | $4.1M | 0.1% | +0% | 14 |
| 96 |  $NBP | NovaBridge Biosciences | $3.9M | 0.1% | -33% | — |
| 97 |  $GTLB | Gitlab Inc. | $3.8M | 0.1% | +25% | 56.8 |
| 98 |  $ODTX | Odyssey Therapeutics, Inc. | $3.7M | 0.1% | NEW | — |
| 99 |  $FHTX | Foghorn Therapeutics Inc. | $3.5M | 0.1% | +0% | 16.1 |
| 100 |  $AGEN | AGENUS INC | $3.3M | 0.1% | +0% | 53.3 |
| 101 |  $MNDY | monday.com Ltd. | $3.1M | 0.1% | +70% | — |
| 102 |  $ZTS | Zoetis Inc. | $2.5M | 0.1% | NEW | 68.6 |
| 103 |  $WK | WORKIVA INC | $2.2M | 0.0% | -51% | 65.4 |
| 104 |  $NFLX | NETFLIX INC | $1.8M | 0.0% | NEW | 78.8 |
| 105 |  $KLRS | Kalaris Therapeutics, Inc. | $1.8M | 0.0% | +0% | — |
| 106 |  $QNT | Quantinuum Inc. | $1.6M | 0.0% | NEW | — |
| 107 |  $RANI | Rani Therapeutics Holdings, Inc. | $1.5M | 0.0% | +0% | — |
| 108 |  $TSLA | Tesla, Inc. | $1.5M | 0.0% | -84% | 53.9 |
| 109 |  $BEKE | KE Holdings Inc. | $1.5M | 0.0% | +0% | — |
| 110 |  $ENTX | Entera Bio Ltd. | $1.3M | 0.0% | NEW | — |
| 111 |  $MDLN | Medline Inc. | $986,000 | 0.0% | +0% | 62.5 |
| 112 |  $LITE | Lumentum Holdings Inc. | $905,253 | 0.0% | NEW | 44.3 |
| 113 |  $FIG | Figma, Inc. | $904,500 | 0.0% | +0% | 43.9 |
| 114 |  $GOSS | Gossamer Bio, Inc. | $857,396 | 0.0% | +0% | 8.2 |
| 115 |  $FOXA | Fox Corp | $521,600 | 0.0% | NEW | 64.5 |
| 116 |  $T | AT&T INC. | $517,500 | 0.0% | NEW | 65.7 |
| 117 |  $NU | Nu Holdings Ltd. | $334,000 | 0.0% | +0% | — |
New Positions (26)
$PBLS Parabilis Medicines, Inc.$81.9M$ABVX Abivax S.A.$76.8M$COAG Hemab Therapeutics Holdings, Inc.$76.6M$RLAY Relay Therapeutics, Inc.$68.3M$KLRA Kailera Therapeutics, Inc.$48.8M$COF CAPITAL ONE FINANCIAL CORP$34.4M$ORKA Oruka Therapeutics, Inc.$23.8M$SPTX Seaport Therapeutics, Inc.$23.8M$TYRA Tyra Biosciences, Inc.$23.2M$ADAG Adagene Inc.$11.2M$MSFTCALL MICROSOFT CORP$9.0M$OCS Oculis Holding AG$8.7M$DSGN Design Therapeutics, Inc.$7.6M$AAPLCALL Apple Inc.$6.7M$ELOX Eloxx Pharmaceuticals, Inc.$5.6M
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Siren, L.L.C. including:
Track Siren, L.L.C.'s Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Siren, L.L.C. and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Siren, L.L.C.
13F Pro is an AI hedge fund tracker and stock research platform. For Siren, L.L.C. (SEC CIK: 2005245), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Siren, L.L.C.'s portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.